Abeona Therapeutics Company Profile (NASDAQ:ABEO)

About Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics logoAbeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ABEO
  • CUSIP: N/A
  • Web: www.abeonatherapeutics.com
Capitalization:
  • Market Cap: $328.34 million
  • Outstanding Shares: 40,255,000
Average Prices:
  • 50 Day Moving Avg: $8.34
  • 200 Day Moving Avg: $6.07
  • 52 Week Range: $3.90 - $10.26
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.19
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $842,999.00
  • Price / Sales: 372.47
  • Book Value: $2.21 per share
  • Price / Book: 3.53
Profitability:
  • EBIDTA: ($23,800,000.00)
  • Net Margins: -2,746.38%
  • Return on Equity: -26.66%
  • Return on Assets: -23.94%
Debt:
  • Current Ratio: 14.08%
  • Quick Ratio: 10.53%
Misc:
  • Average Volume: 496,286 shs.
  • Beta: 2.33
  • Short Ratio: 11.42
 

Frequently Asked Questions for Abeona Therapeutics (NASDAQ:ABEO)

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc. (NASDAQ:ABEO) issued its quarterly earnings data on Tuesday, August, 15th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.07. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.21 million. Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. View Abeona Therapeutics' Earnings History.

When will Abeona Therapeutics make its next earnings announcement?

Abeona Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Abeona Therapeutics.

Where is Abeona Therapeutics' stock going? Where will Abeona Therapeutics' stock price be in 2017?

6 brokerages have issued 12-month price objectives for Abeona Therapeutics' shares. Their predictions range from $15.00 to $22.00. On average, they expect Abeona Therapeutics' share price to reach $19.17 in the next year. View Analyst Ratings for Abeona Therapeutics.

What are analysts saying about Abeona Therapeutics stock?

Here are some recent quotes from research analysts about Abeona Therapeutics stock:

  • 1. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (8/16/2017)
  • 2. Maxim Group analysts commented, "Abeona announced that the company has received guidance from the FDA for accelerating EB-101 (gene therapy corrected skin grafts) into a P3 pivotal program in epidermolysis bullosa (EB). EB-101 has demonstrated proof of concept (POC) data in the first 6 patients of the P1/2 study (Recessive Dystrophic Epidermolysis Bullosa, or RDEB), demonstrating durable wound closure, in some cases for over 3 years (standard skin graft would fall off within a few months). Pending protocol approval, the pivotal program is expected to initiate in early 2018." (7/18/2017)
  • 3. Cantor Fitzgerald analysts commented, "At the ASGCT meeting in Washington D.C., Abeona announced initial 30-day data in two patients treated with a high dose of ABO-102." (5/12/2017)
  • 4. FBR & Co analysts commented, "On March 31, Abeona Therapeutics reported results for a year in which all clinical programs achieved important regulatory and clinical milestones. Most notably, 2016 culminated in the initiation of dosing in the high-dose cohort of Abeona’s Phase I/II trial with ABO-102 in children with Sanfilippo Syndrome Type A (MPS IIIA). We think this milestone is significant as it highlights ABO-102’s continued safety, its promising biopotency, as well as its designation for FDA Fast Track status for a rare pediatric disease, as well as for an orphan disease. It also supports our view that Abeona’s ability to rapidly advance therapies with high-value potential and short pathways to regulatory approval remains under-appreciated. We look next for a clinical update on the EB-101 Phase I study later this month, an update on the Phase I/II study with ABO-101 in MPS IIIB, as well as Abeona’s three other ongoing rare disease programs in the next three to six months to be positive catalysts for ABEO stock." (4/5/2017)

Who are some of Abeona Therapeutics' key competitors?

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the folowing people:

  • Steven H. Rouhandeh, Executive Chairman of the Board
  • Timothy J. Miller Ph.D., President, Chief Executive Officer, Director
  • Jeffrey B. Davis, Chief Operating Officer
  • David P. Nowotnik Ph.D., Senior Vice President - Research and Development
  • Harrison G. Wehner III, Senior Vice President - Plasma
  • Stephen B. Thompson, Chief Accounting Officer, Vice President - Finance, Treasurer, Secretary
  • Michelle Berg, Vice President - Communications & Operations
  • Andre'a Lucca, Vice President - Communications & Operations
  • Phil Maples Ph.D., Vice President - Therapeutics Development and Quality Management
  • Kaye Spratt Ph.D., Vice President - Regulatory & Quality Assurance

Who owns Abeona Therapeutics stock?

Abeona Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.69%), Nexthera Capital LP (0.88%), Royce & Associates LP (0.78%), State Street Corp (0.74%), Northern Trust Corp (0.64%) and Bank of New York Mellon Corp (0.25%). View Institutional Ownership Trends for Abeona Therapeutics.

Who sold Abeona Therapeutics stock? Who is selling Abeona Therapeutics stock?

Abeona Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Nexthera Capital LP. View Insider Buying and Selling for Abeona Therapeutics.

Who bought Abeona Therapeutics stock? Who is buying Abeona Therapeutics stock?

Abeona Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Vanguard Group Inc., Essex Investment Management Co. LLC, TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Teachers Advisors LLC and California State Teachers Retirement System. View Insider Buying and Selling for Abeona Therapeutics.

How do I buy Abeona Therapeutics stock?

Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abeona Therapeutics' stock price today?

One share of Abeona Therapeutics stock can currently be purchased for approximately $7.80.


MarketBeat Community Rating for Abeona Therapeutics (NASDAQ ABEO)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  278
MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Abeona Therapeutics (NASDAQ:ABEO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.17 (145.73% upside)

Analysts' Ratings History for Abeona Therapeutics (NASDAQ:ABEO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Maxim GroupSet Price TargetBuy$17.00HighView Rating Details
7/19/2017HC WainwrightSet Price TargetBuy$20.00MediumView Rating Details
7/18/2017Cantor FitzgeraldSet Price TargetBuy$21.00MediumView Rating Details
6/22/2017Jefferies Group LLCReiterated RatingBuy -> Buy$22.00HighView Rating Details
5/26/2017FBR & CoReiterated RatingBuyN/AView Rating Details
2/7/2017Rodman & RenshawReiterated RatingBuy$17.00 -> $20.00N/AView Rating Details
(Data available from 8/19/2015 forward)

Earnings

Earnings History for Abeona Therapeutics (NASDAQ:ABEO)
Earnings by Quarter for Abeona Therapeutics (NASDAQ:ABEO)
Earnings History by Quarter for Abeona Therapeutics (NASDAQ ABEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017        
8/15/2017Q2 2017($0.14)($0.21)$0.21 million$0.22 millionViewN/AView Earnings Details
5/18/2017Q1 2017($0.15)($0.13)$0.28 million$0.19 millionViewN/AView Earnings Details
3/31/201712/31/2016($0.14)($0.19)$0.19 million$0.26 millionViewN/AView Earnings Details
11/14/2016Q316($0.19)($0.08)$0.23 million$0.18 millionViewN/AView Earnings Details
8/16/2016Q2($0.14)($0.20)$0.27 million$0.21 millionViewN/AView Earnings Details
3/30/2016Q1($0.13)($0.17)$0.22 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Abeona Therapeutics (NASDAQ:ABEO)
2017 EPS Consensus Estimate: ($0.47)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.12)($0.12)($0.12)
Q2 20172($0.12)($0.12)($0.12)
Q3 20172($0.13)($0.11)($0.12)
Q4 20172($0.13)($0.09)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Abeona Therapeutics (NASDAQ:ABEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Abeona Therapeutics (NASDAQ:ABEO)
Insider Ownership Percentage: 6.80%
Institutional Ownership Percentage: 36.15%
Insider Trades by Quarter for Abeona Therapeutics (NASDAQ:ABEO)
Institutional Ownership by Quarter for Abeona Therapeutics (NASDAQ:ABEO)
Insider Trades by Quarter for Abeona Therapeutics (NASDAQ:ABEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2016Todd WiderDirectorBuy5,000$5.48$27,400.00View SEC Filing  
7/31/2015Mark J AhnDirectorBuy18,182$5.50$100,001.00View SEC Filing  
1/26/2015Mark J AhnDirectorBuy25,000$4.00$100,000.00View SEC Filing  
12/24/2014Steven H RouhandehDirectorBuy250,000$4.00$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Abeona Therapeutics (NASDAQ:ABEO)
Latest Headlines for Abeona Therapeutics (NASDAQ:ABEO)
Source:
DateHeadline
americanbankingnews.com logoJefferies Group Comments on Abeona Therapeutics Inc.'s Q3 2017 Earnings (ABEO)
www.americanbankingnews.com - August 18 at 7:20 AM
nasdaq.com logoAbeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017 - Nasdaq
www.nasdaq.com - August 18 at 1:35 AM
bizjournals.com logoLeading Biotech Companies Receiving Orphan Drug Designation in 2017
www.bizjournals.com - August 17 at 3:31 PM
finanznachrichten.de logoABEONA THERAPEUTICS INC
www.finanznachrichten.de - August 17 at 3:31 PM
feeds.benzinga.com logoAbeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017
feeds.benzinga.com - August 17 at 9:55 AM
americanbankingnews.com logoAbeona Therapeutics Inc. (ABEO) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 16 at 9:34 PM
reuters.com logoBRIEF-Abeona Therapeutics expands gene therapy clinical trials in Sanfilippo Syndrome Type A
www.reuters.com - August 16 at 8:24 PM
globenewswire.com logoAbeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome ... - GlobeNewswire (press release)
globenewswire.com - August 16 at 3:21 PM
finance.yahoo.com logoAbeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A
finance.yahoo.com - August 16 at 3:21 PM
americanbankingnews.com logoMaxim Group Analysts Give Abeona Therapeutics Inc. (ABEO) a $17.00 Price Target
www.americanbankingnews.com - August 16 at 3:12 PM
americanbankingnews.com logoAbeona Therapeutics Inc. (ABEO) Releases Earnings Results, Misses Expectations By $0.07 EPS
www.americanbankingnews.com - August 16 at 10:38 AM
globenewswire.com logoAbeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights - GlobeNewswire (press release)
globenewswire.com - August 15 at 3:22 PM
finance.yahoo.com logoAbeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights
finance.yahoo.com - August 15 at 3:22 PM
finance.yahoo.com logoAbeona Therapeutics reports 2Q loss
finance.yahoo.com - August 15 at 3:22 PM
americanbankingnews.com logo Brokerages Anticipate Abeona Therapeutics Inc. (ABEO) Will Post Quarterly Sales of $230,000.00
www.americanbankingnews.com - August 14 at 10:14 AM
americanbankingnews.com logo Analysts Anticipate Abeona Therapeutics Inc. (NASDAQ:ABEO) Will Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - August 12 at 2:12 AM
prnewswire.com logoTop Companies Receiving Orphan Drug Designation in 2017
www.prnewswire.com - July 28 at 3:28 PM
americanbankingnews.com logoAbeona Therapeutics Inc. (NASDAQ:ABEO) Expected to Announce Quarterly Sales of $230,000.00
www.americanbankingnews.com - July 26 at 10:37 AM
streetinsider.com logoAbeona Therapeutics (ABEO) Appoints Juan Ruiz as CMO - StreetInsider.com
www.streetinsider.com - July 26 at 1:22 AM
americanbankingnews.com logoAbeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 25 at 3:07 PM
bizjournals.com logoGlobal Genes Announces RARE Champion of Hope Award Recipients to be Honored at 6th Annual RARE Tribute and Patient Advocacy Summit
www.bizjournals.com - July 25 at 12:03 AM
americanbankingnews.com logo Brokerages Anticipate Abeona Therapeutics Inc (NASDAQ:ABEO) Will Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - July 24 at 10:18 PM
marketbeat.com logoSTORY REMOVED: BC-US--Earns-Abeona Therapeutics
marketbeat.com - July 21 at 4:46 PM
finance.yahoo.com logoAbeona Therapeutics reports 4Q loss
finance.yahoo.com - July 21 at 4:29 PM
americanbankingnews.com logoHC Wainwright Analysts Give Abeona Therapeutics Inc. (NASDAQ:ABEO) a $20.00 Price Target
www.americanbankingnews.com - July 20 at 12:58 AM
americanbankingnews.com logoCantor Fitzgerald Reiterates "$21.00" Price Target for Abeona Therapeutics Inc. (ABEO)
www.americanbankingnews.com - July 18 at 5:30 PM
nasdaq.com logoAbeona Therapeutics Receives Guidance from FDA to Commence ... - Nasdaq
www.nasdaq.com - July 18 at 3:20 PM
finance.yahoo.com logoAbeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa
finance.yahoo.com - July 18 at 3:20 PM
americanbankingnews.com logoAbeona Therapeutics Inc. (ABEO) Receives Buy Rating from Maxim Group
www.americanbankingnews.com - July 18 at 3:10 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE- Abercombie, Clubcorp, Inotek, PayPal - Nasdaq
www.nasdaq.com - July 10 at 3:24 PM
finance.yahoo.com logoETFs with exposure to Abeona Therapeutics, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 3:24 PM
americanbankingnews.com logoAbeona Therapeutics Inc. (ABEO) Raised to Buy at BidaskClub
www.americanbankingnews.com - July 8 at 2:20 PM
finance.yahoo.com logoAhead of this year's MLB All-Star Game, here are 4 home r...
finance.yahoo.com - July 8 at 8:19 AM
nasdaq.com logoAbeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6% - Nasdaq
www.nasdaq.com - July 6 at 4:40 PM
finance.yahoo.com logoAbeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6%
finance.yahoo.com - July 6 at 4:40 PM
marketwatch.com logoThe 11 Biggest and Best Analyst Upgrades of June
www.marketwatch.com - July 1 at 3:18 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces FDA Orphan Drug Designation for ABO-201 - StreetInsider.com
www.streetinsider.com - June 30 at 8:26 PM
americanbankingnews.com logoAbeona Therapeutics Inc. (ABEO) Expected to Post Quarterly Sales of $230,000.00
www.americanbankingnews.com - June 30 at 12:25 PM
americanbankingnews.com logoAbeona Therapeutics Inc. (ABEO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 30 at 8:37 AM
globenewswire.com logoAbeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy ... - GlobeNewswire (press release)
globenewswire.com - June 29 at 3:19 PM
finance.yahoo.com logoAbeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program
finance.yahoo.com - June 29 at 3:19 PM
americanbankingnews.com logoAbeona Therapeutics Inc. (ABEO) Expected to Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - June 28 at 6:28 PM
finance.yahoo.com logoETFs with exposure to Abeona Therapeutics, Inc. : June 28, 2017
finance.yahoo.com - June 28 at 3:36 PM
forbes.com logoRare Diseases: Biotech's High Risk, Highest Reward Sub-Sector - Forbes
www.forbes.com - June 27 at 3:20 PM
finance.yahoo.com logoRare Diseases: Biotech's High Risk, Highest Reward Sub-Sector
finance.yahoo.com - June 27 at 3:20 PM
americanbankingnews.com logoBrokers Set Expectations for Abeona Therapeutics Inc.'s Q3 2017 Earnings (ABEO)
www.americanbankingnews.com - June 26 at 7:41 AM
americanbankingnews.com logoAbeona Therapeutics Inc. (ABEO) Expected to Earn Q2 2017 Earnings of ($0.12) Per Share
www.americanbankingnews.com - June 23 at 8:33 AM
americanbankingnews.com logoAbeona Therapeutics Inc. (ABEO) Now Covered by Analysts at Jefferies Group LLC
www.americanbankingnews.com - June 22 at 11:02 AM
finance.yahoo.com logoETFs with exposure to Abeona Therapeutics, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 8:21 PM
americanbankingnews.com logoAbeona Therapeutics Inc (ABEO) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - June 9 at 10:10 PM

Social

Chart

Abeona Therapeutics (ABEO) Chart for Saturday, August, 19, 2017

This page was last updated on 8/19/2017 by MarketBeat.com Staff